ClinicalTrials.gg
CompletedNCT04204408FRONTIER1Updated Dec 19, 2025

A Research Study Investigating Mim8 in People With Haemophilia A

A Phase 2 interventional study of NNC0365-3769 (Mim8) and Placebo (Mim8) in Healthy Volunteers and Haemophilia A With or Without Inhibitors, sponsored by Novo Nordisk A/S. Completed at 40 sites in 12 countries. Open to male participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
12 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Enrollment
3rd of 59
275 · median 38
Started
2020
with 2 others
Phase 2
7 of 92
none open now
Registered
69th of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 3rd largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 69th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected with a thin needle in the skin of the stomach, using a pen-injector.

The study will last for up to 44 months. It consists of a main phase (part 1 and part 2) and an extension phase. In part 1, participants will be injected only once with either Mim8 or a "dummy" medicine (placebo) - which one will be decided by chance. In part 2 and the extension phase participants will get an Mim8 injection weekly or monthly.

03

Conditions studied

  • Healthy Volunteers
  • Haemophilia A With or Without Inhibitors

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Single ascending dose part 1:

  • Male, aged 18-45 years (both inclusive) at the time of signing
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator

Multiple ascending dose part 2:

  • Male, aged 12-64 years (both inclusive) at the time of signing informed consent (Germany and Japan have local requirements)
  • Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical records

Exploratory biomarker cohort:

  • Male, aged equal to or above 12 years at the time of signing informed consent (Germany and Japan have local requirements)
  • Diagnosis of congenital haemophilia A with FVIII activity below 1% based on medical recordsv

Exclusion criteria

Exclusion Criteria:

Part 1:

  • Factor VIII activity equal to or above 150% at screening
  • Increased risk of thrombosis, e.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease

Part 2:

  • Known congenital or acquired coagulation disorders other than haemophilia A
  • Increased risk of thrombosis as evaluated by the investigator. E.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Advanced atherosclerotic disease (e.g. known history of ischemic heart disease, ischemic stroke) as evaluated by the investigator
  • Any disease that may increase the risk of thrombosis
  • Receipt of emicizumab or drugs with similar modes of action within 5 half-lives before trial product administration
  • Ongoing or planned immune tolerance induction therapy

Exploratory biomarker cohort:

  • Known congenital or acquired coagulation disorders other than haemophilia A
  • Increased risk of thrombosis as evaluated by the investigator. E.g. known history of personal or first degree relative(s) with unprovoked deep vein thrombosis with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Any clinical signs or established diagnosis of venous or arterial thromboembolic disease with exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing
  • Advanced atherosclerotic disease (e.g. known history of ischemic heart disease, ischemic stroke) as evaluated by the investigator
  • Any autoimmune disease that may increase the risk of thrombosis
  • Ongoing or planned immune tolerance induction therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
275 participants (actual)

Study arms

  • Experimental
    Single dose (part 1) Mim8

    Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.

    Drug: NNC0365-3769 (Mim8)

  • Placebo comparator
    Single dose (part 1) placebo

    Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.

    Drug: Placebo (Mim8)

  • Experimental
    Multiple dose (part 2)

    Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.

    Drug: NNC0365-3769 (Mim8)

Interventions

  • Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses

  • DrugPlacebo (Mim8)

    Mim8 placebo administered subcutaneously (s.c., under the skin)

06

What researchers measure

Primary outcomes

  1. Part 1: Number of treatment emergent adverse events

    Count

    Time frame: From time of dosing (Day 1) to Week 16

  2. Part 2: Number of treatment emergent adverse events

    Count

    Time frame: From time of first dosing (Day 1) to Week 12

  3. Part 2, extension: Number of treatment emergent adverse events

    Count

    Time frame: From Week 12 up to Week 176 (16 weeks after last dose)

Secondary outcomes

  1. Part 1: Number of injection site reactions

    Count

    Time frame: From time of dosing (Day 1) to Week 16

  2. Part 1: Relative change in D-dimer

    Percent

    Time frame: From baseline (Day 1) to Week 16

  3. Part 1: Relative change in prothrombin fragment 1 and 2

    Percent

    Time frame: From baseline (Day 1) to Week 16

  4. Part 1: Relative change in fibrinogen

    Percent

    Time frame: From baseline (Day 1) to Week 16

  5. Part 1: Relative change in platelets

    Percent

    Time frame: From baseline (Day 1) to Week 16

  6. Part 1: Cmax, SD: the maximum concentration of Mim8 after a single dose

    μg/mL

    Time frame: From baseline (Day 1) to Week 16

  7. Part 1: AUC0-inf, SD: the area under the Mim8 concentration-time curve from time 0 to infinity after a single dose

    μg\*day/mL

    Time frame: From baseline (Day 1) to Week 16

  8. Part 1: t1/2, SD: the terminal half-life of Mim8 after a single dose

    Days

    Time frame: From baseline (Day 1) to Week 16

  9. Part 1: tmax, SD: the time to maximum concentration of Mim8 after a single dose

    Days

    Time frame: From baseline (Day 1) to Week 16

  10. Part 1: Change in activated partial thromboplastin time

    Seconds

    Time frame: From baseline (Day 1) to Week 16

  11. Part 2 (weekly and monthly dosing): Number of injection site reactions

    Count

    Time frame: From time of first dosing (Day 1) to Week 12

  12. Part 2 (weekly and monthly dosing): Occurrence of anti-Mim8 antibodies

    Count

    Time frame: From baseline (Day 1) to Week 12

  13. Part 2 (weekly and monthly dosing): Relative change in D-dimer

    Percent

    Time frame: From baseline (Day 1) to Week 12

  14. Part 2 (weekly and monthly dosing): Relative change in prothrombin fragment 1 and 2

    Percent

    Time frame: From baseline (Day 1) to Week 12

  15. Part 2 (weekly and monthly dosing): Relative change in fibrinogen

    Percent

    Time frame: From baseline (Day 1) to Week 12

  16. Part 2 (weekly and monthly dosing): Relative change in platelets

    Percent

    Time frame: From baseline (Day 1) to Week 12

  17. Part 2 PK session 2 (weekly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses

    μg/mL

    Time frame: From Day 57 to Day 64

  18. Part 2 PK session 2 (weekly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses

    μg\*day/mL

    Time frame: From Day 57 to Day 64

  19. Part 2 PK session 2 (monthly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses

    μg/mL

    Time frame: From Day 57 to Day 85

  20. Part 2 PK session 2 (monthly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses

    μg\*day/mL

    Time frame: From Day 57 to Day 85

  21. Part 2 (weekly dosing): Mean of maximum thrombin generation (peak height)

    nM

    Time frame: From Day 57 to Day 64

  22. Part 2 (monthly dosing): Mean of maximum thrombin generation (peak height)

    nM

    Time frame: From Day 57 to Day 85

  23. Part 2, extension: Number of injection site reactions

    Count

    Time frame: From Week 12 up to Week 176 (16 weeks after last dose)

  24. Part 2, extension: Occurrence of anti-Mim8 antibodies

    Count

    Time frame: From Week 12 up to Week 176 (16 weeks after last dose)

07

Study locations

40 sites
  • Arizona H&T Phoenix Child Hosp
    Phoenix, Arizona 85016-7710, United States
  • Children's Hospital Los Angeles - Endocrinology
    Los Angeles, California 90027, United States
  • Children's Healthcare Atlanta
    Atlanta, Georgia 30322, United States
  • Rush University Med. Cntr
    Chicago, Illinois 60612, United States
  • University of Iowa_Iowa City
    Iowa City, Iowa 52242, United States
  • University Of Michigan
    Ann Arbor, Michigan 48109, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Michigan State University
    East Lansing, Michigan 48823, United States
  • St. Jude Clinic Novant Health
    Charlotte, North Carolina 28204, United States
  • Cincinnati Child's Hsp Med Ctr
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Dayton Children Hemostati Ctr
    Dayton, Ohio 45404, United States
  • Penn State MS Hershey Med Ctr
    Hershey, Pennsylvania 17033-2360, United States
  • Vanderbilt Hemostasis Thrombosis Clinic
    Nashville, Tennessee 37232, United States
  • Versiti, CCBD
    Milwaukee, Wisconsin 53226, United States
  • Universitätsklinik für Innere Medizin V
    Innsbruck, 6020, Austria
  • Universitätsklinik für Innere Medizin V
    Innsbruck, A 6020, Austria
  • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
    Sofia, 1527, Bulgaria
  • Charité - Campus Charité Mitte - Charité Research Organisation GmbH
    Berlin, 10117, Germany
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Berlin, 10249, Germany
  • Istituto di Medicina Int. A. Bianchi Bonomi Univ. Milano
    Milan, MI 20124, Italy
  • Policlinico Umberto I Sezione Ematologia
    Roma, 00161, Italy
  • Nagoya University Hospital_Blood Transfusion
    Aichi, 466-8560, Japan
  • Nara Medical University Hospital_Pediatrics
    Nara, 634-8522, Japan
  • Tokyo Medical Univ. Hospital_Laboratory Medicine
    Tokyo, 160-0023, Japan
  • Uniwersytecki Szpital Kliniczny W Poznaniu
    Poznan, Greater Poland Voivodeship 60-569, Poland
  • Instytut Hematologii i Transfuzjologii
    Warsaw, Masovian Voivodeship 02-776, Poland
  • Szpital Uniwersytecki, Oddzial Kliniczny Hematologii
    Krakow, 30-688, Poland
  • Charlotte Maxeke Johannesburg Academic Hospital
    Parktown, Johannesburg, Gauteng 2193, South Africa
  • Pietersburg Hospital
    Polokwane, Limpopo 0699, South Africa
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, 29010, Spain
  • Hospital La Fe - Hemostasia y Trombosis
    Valencia, 46026, Spain
  • Universitätsklinik für Hämatologie
    Bern, 3010, Switzerland
  • Universitätsspital Zürich - Klinik für Medizinische Onkologie und Hämatologie
    Zurich, 8091, Switzerland
  • Hacettepe Üniversitesi Hastanesi- Endokrinoloji
    Ankara, 06230, Turkey (Türkiye)
  • Trakya Üniversitesi Tıp Fakültesi Hastanesi- Kardiyoloji
    Edirne, 22030, Turkey (Türkiye)
  • Ege Üniversitesi Hastanesi- Hematoloji
    Izmir, 35100, Turkey (Türkiye)
  • Royal Free Haemophilia Comprehensive Care Centre
    London, NW3 2QG, United Kingdom
  • Oxford Haemophilia Comprehensive Care Center
    Oxford, OX3 7LJ, United Kingdom
08

References and documents

Publications

  • Chowdary P, Lentz SR, Gil L, Lopez-Jaime FJ, Windyga J, Ong Clausen WH, Laursen PN, Mahlangu J. FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in people with hemophilia A. Res Pract Thromb Haemost. 2025 Oct 8;9(7):103207. doi: 10.1016/j.rpth.2025.103207. eCollection 2025 Oct. PubMed 41246456 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Oct 2023, 44 months.

Of 18 phase 2 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2019
First posted
Dec 19, 2019
StartActual
Jan 10, 2020
Primary completionActual
Oct 6, 2023
CompletionActual
Oct 6, 2023
Results delay requested
Oct 4, 2024
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04204408
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 19, 2019
Start date
Jan 10, 2020
Primary completion
Oct 6, 2023
Completion
Oct 6, 2023
Last update
Dec 19, 2025

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denecimig

Start the discussion